Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.00 1.95% 209.00 209.00 211.00 211.00 205.00 206.50 152,251 16:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.4 15.5 2.3 89.3 1,399

Syncona Share Discussion Threads

Showing 18676 to 18697 of 18900 messages
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
DateSubjectAuthorDiscuss
07/12/2019
11:46
I expect to see a rerating of Syncona in 2020 as several of their investments enter the clinical stage.In addition, Autolus, which is around 30%, owned by Syncona should on positive data scale $20 plus over the coming months which should be reflected with an increase in the Syncona share price
ltinvestor
07/12/2019
11:37
Don’t understand that whilst Autolus is much stronger, SYNC remains flat. My understanding was Autolus was dragging Sync but that shouldn’t be the case anymore?
1seanshare
07/12/2019
11:19
Autolus and Freeline are both presenting updates at the ASH conference being held in Orlando this weekend.Looking forward in particular to more data being released by Autolus and progress to date...
ltinvestor
03/12/2019
10:46
The NASDAQ market likes the recent updates from Autolus. Share price up 50% (valuation up $250m) in 1 month.
luxaeterna1
13/11/2019
16:11
LONDON, November 13, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovative cancer immunotherapies, today announced that they have entered into a license agreement whereby Autolus will have the right to develop CAR T cell therapies incorporating Noile-Immune’s PRIME (proliferation-inducing and migration-enhancing) technology secreting both IL-7 and CCL19. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient’s own T cells.
brexitplus
05/11/2019
14:57
Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting Autolus Therapeutics plc a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced today pre-clinical data on AUTO6NG, the company’s next generation GD2-targeting CAR T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-10, 2019, in Washington, D.C.AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFb and checkpoint inhibition for relapsed/refractory neuroblastoma. Background Neuroblastoma is the most common extracranial solid cancer in children with poor long-term survival in those with high-risk disease. A currently ongoing phase I clinical study of GD2-targeted CART for refractory/relapsed neuroblastoma (NCT02761915) shows activity against disseminated disease without inducing on target/off tumor toxicity. However, CART persistence was limited and clinical activity transient and incomplete. Building on the GD2 CAR used in this study, we have developed a next generation T-cell product candidate termed AUTO6NG. The AUTO6NG product consists of 3 distinct populations of GD2-targeted CAR T-cells, produced by dual transduction of T-cells with two separate retroviral vectors. The first vector directs the expression of a GD2-targeting CAR, co-expressed with a constitutively signalling IL7 cytokine receptor (IL7R_CCR) (product A), while the second vector is a tri-cistronic retroviral vector encoding the same GD2 CAR, co-expressed with dominant negative TGFbRII (dnTGFbRII) and truncated SHP2 (dSHP2) (product B). dSHP2 confers resistance to inhibitory signals such as those from PD1. Methods Human T-cells were either dual transduced with both vectors yielding a mix of product A/B/A+B (AUTO6NG) or single transduced with each vector individually giving raise to product A or B. Both single and dual transduced CAR T-cells were extensively evaluated in vitro for redirected lysis, cytokine secretion, T-cell proliferation and survival and resistance to immunosuppressive pathways (including TGFb and PD1/PDL1 inhibition) in co-culture assays with GD2-positive and negative tumour cell lines. Additionally, anti-tumour activity of AUTO6NG was evaluated in vivo by intravenous administration in an established neuroblastoma xenograft model in NSG mice. Results AUTO6NG T-cells (product A/B/A+B) were highly potent in cytotoxicity assays against GD2 positive tumour cell lines with no differences observed compared with single transduced CAR T-cells (product A or B). Expression of the IL7R_CCR in both AUTO6NG and product A conferred exogenous-cytokine-independent viability and homeostatic proliferation of modified T-cells, without causing autonomous T-cell growth. Furthermore, AUOTO6NG T-cells and product B but not product A proved resistant to both TGFb- and PD1/PDL1-mediated immunosuppression in vitro due to the presence of dnTGFbRII and dSHP2 in those genetically engineered CAR T-cells. Finally, intravenous delivery of AUTO6NG exhibited potent anti-tumour activity and extended survival in NSG mice with established tumour burden. Conclusions These results demonstrate the feasibility, safety, and efficacy of AUTO6NG T-cells. The addition of IL7R_CCR, dnTGFbRII and dSHP2 modules to the AUTO6NG product augment its functions by extending T-cell persistence and rendering modified T-cells resistant to TGFb- and PD1/PDL1-driven immune inhibition.
brexitplus
05/11/2019
11:46
Thanks Tiger Autolus Therapeutics to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7
brexitplus
05/11/2019
11:27
Hi brexitplus Not sure if that would include Autolus as already sold from the two unit trusts, only held in Patient Capital which now has Schroders in place to manage it. That said, good to see a line being drawn under some of the Woodford wreckage and some better sentiment towards particularly the unquoted pharma/life sciences sector would be good all round.
tiger blue
05/11/2019
11:15
AUTOLUS??? A consortium led by a specialist life sciences investment bank is close to entering exclusive talks to buy £500m of healthcare assets accumulated by the fallen star fund manager Neil Woodford. Sky News has learnt that WG Partners, which has assembled a cluster of financial and industry backers including pharmaceuticals investor Ricanto, is the frontrunner to buy roughly 15 positions held by Woodford Investment Management (WIM). Insiders said the WG-led consortium could secure a period of exclusivity within which to conclude a deal as early as Monday. The prospective deal comes weeks after Mr Woodford - arguably Britain's best-known retail fund manager - announced that he was shutting his firm amid a deepening crisis. Other bidders for the portfolio of stakes in listed and privately owned healthcare companies included Rosetta Capital, a life sciences-focused venture fund, and Omega, a hedge fund. The overall portfolio being pursued by the WG Partners consortium is understood to be valued at close to £500m, according to one insider. It excludes WIM's holding in BenevolentAI, which uses artificial intelligence to aid drug discovery and which recently saw its valuation halve in a funding round led by the Singaporean state fund Temasek Holdings. Among the companies included in the proposed transaction are Oxford Nanopore, a DNA sequencing specialist; 4D Pharma, a biotherapeutics specialist; Mereo BioPharma Group, a rare diseases specialist quoted in New York and London; and Rutherford Health, a listed proton beam therapy business formerly called Proton Partners. The company stakes vary widely in size and value, and a deal is expected to take several weeks to conclude. WG is said to be in the process of finalising the necessary financing to complete the acquisition. Mr Woodford became Britain's most prominent biotech investor, but has seen many of those bets turn sour amid uncertainty about the companies' ultimate chances of success. The sale, which is being overseen by PJT Park Hill Partners, also includes stakes in Arix Bioscience, Immunocore, Kymab, Verseon and 4D Pharma, according to insiders. Once completed, the deal will mark a further step towards the winding-up of Mr Woodford's eponymous asset management firm.
brexitplus
24/10/2019
11:52
Bull flag on the chart, I am watching closely but in (STX) which has gone very well since 30p’s, now 184p but US commercialization deal should see a run up to 250/275p this quarter, if that happens I will free up a bit of cash for a stake here.
ny boy
22/10/2019
14:18
Gyroscope's Dry AMD eye clinical trials will have data from the the first cohort of patients from around December 2019. I am basing this from the RNS saying January 2019 had the first dosed patient, combined with a trial length of 48 weeks as per the official trial registration. Interesting times - they now have 7 trial locations recruiting in the UK. I am not clear if these are referral centres, or surgery locations. Full data on P1/2 in early 2021.
luxaeterna1
16/9/2019
15:15
With the Freeline pipeline expanding, I am pleased to see progres and if they are getting more comfortable with the technology, I note they have planned pre-clinical trials for: Gaucher disease, Haemophilia A and an inflammation disease planned. Hopefully they can start a new trial every 4-6 months from now on. I'm hoping anyway!
luxaeterna1
12/9/2019
07:16
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced dosing of the first patient in its MARVEL1 study, a multi-centre Phase 1/2 clinical trial of its liver-directed AAV gene therapy for Fabry Disease. The MARVEL1 study is the first clinical-stage adeno-associated virus (AAV) gene therapy study globally for Fabry Disease. The programme leverages Freeline’s proprietary gene therapy platform, including its novel capsid, which has already shown clinical benefit for Haemophilia B patients. Fabry disease is a type of lysosomal storage disorder in which certain fatty molecules are not properly metabolised. Patients have a genetic mutation which leads to a deficiency of α-galactosidase A enzyme (αGLA) resulting in an accumulation of lipids, such as globotriaosylceramide (Gb3) and globotriaosylsphingosine (LysoGb3), throughout the body. This can cause highly debilitating progressive multi-organ disease. It is estimated that Fabry Disease affects one in every 40,000* people. It is currently treated by enzyme replacement therapy (ERT), which requires regular and expensive infusions. The MARVEL1 study aims to deliver a replacement copy of the missing gene to the liver, which will then produce continuous high levels of αGLA, offering the potential for therapy with a single treatment. MARVEL1 is a multi-centre, international, dose-escalating Phase 1/2 study in adult males with classic Fabry Disease. The study is focused on assessing the safety of FLT190, and its ability to lead to continuous high levels of αGLA production. In addition to safety, endpoints in the study include clearance of Gb3 and LysoGb3 from the plasma, changes in renal and skin biopsies, renal and cardiac function, GLA immune response, viral shedding and quality of life. Freeline published preclinical data on its Fabry programme in February 2019 at the WORLD Symposium in Orlando and presented further data in May 2019 at the Update on Fabry Disease in Prague, showing that a single dose of its liver-directed AAV gene therapy was able to correct disease in Fabry knockout mice. Freeline has shown long-term follow-up of sustained levels of GLA activity in Fabry knock-out mice and significant reductions of Gb3 in plasma and urine as well as the key disease tissues of kidney and heart, with no adverse effects being observed. Prof. Derralynn Hughes, Royal Free Hospital, London, UK “The initiation of this clinical study is an important event for the patient community. I am hopeful that the promising preclinical data will translate into long term benefit for patients with Fabry Disease.” “The initiation of our MARVEL1 study and dosing of the first patient is a significant milestone for Freeline,” said Chris Hollowood, Executive Chairman of Freeline. “Continuous high expression of alpha GLA holds the potential for better treatment outcomes than is seen with ERT, the current standard of care. We believe we can access high expression at relatively low doses. With two programmes in the clinic on a common proprietary gene therapy platform, Freeline are building a leading systemic gene therapy company using next-generation AAV technology. These innovative gene therapies have the potential to change patients’ lives.”
brexitplus
09/9/2019
07:31
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, presented further follow-up data on FLT180a, its AAV gene therapy programme for Haemophilia B, for the first cohort of two patients at the Joint 10th BIC and the 3rd Inhibitor International Conferences (Italy), 6 – 8 September 2019. Pratima Chowdary, the principal investigator for the FLT180a programme, presented the latest data from the first cohort of two patients who were treated with the lowest study dose (4.5x1011vg/kg). A single infusion at this low dose was well tolerated by patients with severe Haemophilia B with no infusion related reactions. FIX activity remains stable and consistent post steady state at 40 +-5.5 over 66 weeks and 74 weeks post-administration, respectively, with no evidence of transaminitis. Both patients remained free of spontaneous bleeding episodes and did not require any Factor IX supplementation. The Freeline FLT180a programme uses the company’s AAVS3 capsid and a gain of function variant of human factor IX (FIX). The therapy is being evaluated in collaboration with UCL in a Phase 1/2 trial known by Freeline as B-AMAZE, with the goal of normalising FIX activity in patients with moderate and severe Haemophilia B. Principal investigator Pratima Chowdary said: “The data is encouraging, showing durability of clinical results for FLT-180a. We are currently progressing the study to identify a dose level that leads to normalisation of FIX activity levels with minimal or no toxicity.”
brexitplus
07/9/2019
14:58
Will be interesting to see of Syncona has bought more.
brexitplus
07/9/2019
08:07
I think that Woodford will be forced to sell his total holding in Autolus.There appears to be no shortage of buyers for his stock.....He can now sell at $14
ltinvestor
06/9/2019
16:12
Worth watching on the monitor, Autolus is up 65% on yesterday $9.85 to $16+ in 24 hours.
luxaeterna1
06/9/2019
15:35
Citywire reporting that Woodford has sold Autolus from his Equity Income & Income Focus funds. They think he has retained the Patient Capital holding. AUTL up again today.
tiger blue
06/9/2019
08:00
TB. Certainly looks that way...
ltinvestor
05/9/2019
22:02
Autolus up 21.7% today, nice but nothing to celebrate given the extent of the decline. More important was the volume of 7.8m shares, methinks some stock overhang has finally moved on, hopefully Woodford into safer hands
tiger blue
05/9/2019
10:22
Autolus updated corporate presentation a couple of days ago. Seems all systems are go and the management team are keen to push things along now hxxps://autolus.gcs-web.com/static-files/d053be07-f6a1-4762-b96f-2eac212b811d
luxaeterna1
03/9/2019
11:36
Autolus Therapeutics today announced that the journal Nature Medicine has published both pre-clinical results and clinical data from the ongoing Phase I CARPALL trial of AUTO1, demonstrating the potential of the company’s novel CAR T therapy targeting CD19 in development for the treatment of pediatric acute lymphoblastic leukemia (ALL). The paper reports that AUTO1, or CAT Chimeric Antigen Receptor T cells (CAT CAR T), utilizes a binder with a fast off rate and showed both increased proliferation/ cytotoxicity in vitro and enhanced proliferative capacity and anti-tumor activity when compared to FMC63 CAR T therapies in vivo. In the Phase 1 clinical trial, 86% (n=14) of recurrent/refractory pediatric ALL patients achieved molecular complete remission after a single dose, with a median duration of remission of 7.4 months and no severe cytokine release syndrome (CRS; ≥ grade 3 or 4), in this relapsed and/or refractory patient population.
alan@bj
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220811 05:44:32